Noxap (Nitric Oxide)

Nitric oxide, the active ingredient in Noxap, is a gasotransmitter presented as an inhalation gas for respiratory and cardiovascular use. It acts as a pulmonary vasodilator, helping to manage pulmonary hypertension and improve oxygenation in critical care settings. GNH USA supplies Noxap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Noxap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Noxap is used in the management of conditions that involve elevated pulmonary vascular resistance and impaired gas exchange.

- Pulmonary hypertension: reduces pulmonary arterial pressure and improves exercise capacity. - Acute respiratory distress syndrome (ARDS): enhances oxygenation by dilating pulmonary vessels. - Neonatal persistent pulmonary hypertension of the newborn (PPHN): lowers pulmonary artery pressure to support transition to extra‑uterine life. - Peri‑operative pulmonary vasodilation: stabilises haemodynamics during cardiac surgery. - Right‑heart failure secondary to pulmonary hypertension: alleviates right‑ventricular afterload. - Chronic obstructive pulmonary disease (COPD) exacerbations: improves ventilation‑perfusion matching.

Adverse reactions to inhaled nitric oxide are generally related to its vasodilatory activity and the delivery system.

Common Side Effects: - Methemoglobinemia: dose‑dependent increase in methemoglobin levels. - Nitrogen dioxide (NO2) formation: irritant gas produced when NO reacts with oxygen. - Rebound pulmonary hypertension: rise in pulmonary pressure after abrupt discontinuation. - Hypotension: systemic blood pressure reduction if high doses are used. - Headache: mild, transient headache associated with vasodilation. - Cough or throat irritation: local airway discomfort during inhalation.

Serious or Rare Side Effects: - Severe methemoglobinemia: symptomatic levels requiring treatment. - Persistent rebound pulmonary hypertension: may need rescue therapy. - Acute kidney injury: reported in rare cases with prolonged high‑dose exposure. - Hemolysis: especially in patients with glucose‑6‑phosphate dehydrogenase deficiency. - Pulmonary edema: rare accumulation of fluid in the lungs. - Allergic reaction: anaphylaxis or severe hypersensitivity to the delivery system.

When using inhaled nitric oxide, clinicians should observe specific safety measures and patient monitoring.

- Dose titration: adjust to the lowest effective concentration to achieve target oxygenation. - Methemoglobin monitoring: regularly check levels to keep them below 5 %. - NO2 monitoring: ensure nitrogen dioxide concentrations remain below safe limits. - Abrupt discontinuation: avoid sudden cessation to prevent rebound pulmonary hypertension. - Contraindications: do not use in patients with known hypersensitivity to nitric oxide or its delivery components. - Store at ambient temperature: keep the gas cylinders in a well‑ventilated, dry area, protected from direct sunlight and extreme temperatures.

Inhaled nitric oxide may interact with other agents that affect vascular tone or hemoglobin.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive pulmonary vasodilation may cause severe hypotension. - Methylene blue: can reverse methemoglobinemia but may interfere with nitric oxide’s efficacy.

Moderate Interactions (Monitor Closely): - Inhaled bronchodilators (e.g., albuterol): may enhance vasodilatory response, requiring blood pressure monitoring. - Hemoglobin‑modifying agents (e.g., nitrites): increase risk of methemoglobinemia. - General anesthetics (e.g., volatile agents): may potentiate systemic hypotension. - Anticoagulants: monitor for bleeding if pulmonary pressures change rapidly. - High‑flow oxygen therapy: can increase NO2 formation, necessitating careful gas monitoring.